Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of Anesthesia on Maternal and Fetal Oxidative Stress During Cesarean Delivery

5 novembre 2026 mis à jour par: University of Banja Luka

The Impact of Target-Controlled Infusion of Propofol on Fetal Oxidative Stress During Anesthesia for Cesarean Section

Oxidative stress occurs when the production of reactive molecules exceeds the body's antioxidant defenses. Pregnancy is associated with physiological changes that may increase oxidative stress in both the mother and fetus. The type of anesthesia used during cesarean delivery may influence this process.

This study aimed to investigate whether general anesthesia using target-controlled infusion (TCI) of propofol affects maternal and fetal oxidative stress compared with spinal anesthesia and general anesthesia using thiopental and sevoflurane.

A total of 90 healthy pregnant women undergoing elective cesarean delivery were included in this prospective study. Participants were divided into three groups of 30: spinal anesthesia, propofol-based general anesthesia, and thiopental-sevoflurane general anesthesia.

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess biochemical markers of oxidative stress and antioxidant defense. Clinical and anesthesia-related data were also recorded.

The study was designed to compare oxidative stress markers across the three anesthesia techniques and evaluate the potential antioxidant effects of propofol on the mother and fetus.

Aperçu de l'étude

Description détaillée

This prospective, open-label clinical study was conducted at the University Clinical Centre of the Republic of Srpska in Banja Luka, Bosnia and Herzegovina, to investigate the effects of different anesthetic techniques on maternal and fetal oxidative stress during elective cesarean delivery.

The study included 90 pregnant women with uncomplicated pregnancies undergoing elective cesarean delivery. Participants were allocated to three groups of 30 according to the anesthetic technique: spinal anesthesia (Group S), general anesthesia with target-controlled infusion of propofol (Group P), and general anesthesia with thiopental induction followed by sevoflurane maintenance (Group TS).

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess oxidative stress and antioxidant defense mechanisms. The biochemical analyses included markers of lipid peroxidation, reactive oxygen species, and antioxidant activity, including thiobarbituric acid-reactive substances (TBARS), nitrites, hydrogen peroxide, superoxide anion, superoxide dismutase (SOD), reduced glutathione (GSH), and catalase (CAT).

Maternal hemodynamic parameters, anesthetic drug administration, neonatal clinical outcomes, and postoperative maternal outcomes were also evaluated.

The study aimed to compare oxidative stress responses across the three anesthetic techniques and investigate whether propofol-based total intravenous anesthesia provides potential antioxidant benefits in the maternal-placental-fetal system.

Type d'étude

Interventionnel

Inscription (Réel)

90

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnie Herzégovine, 78000
        • University Clinical Centre of the Republic of Srpska

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Uncomplicated singleton pregnancy.
  • Estimated fetal weight greater than 2500 g.
  • Scheduled elective cesarean delivery.
  • Written informed consent to participate in the study.

Exclusion Criteria:

  • Emergency cesarean delivery.
  • Thrombophilia.
  • Hypertensive disorders of pregnancy.
  • Diabetes mellitus.
  • Maternal smoking.
  • Intrauterine fetal growth restriction (IUGR).
  • Fetal malformations.
  • Intrauterine fetal death.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm 1 - Spinal anesthesia

Thirty women undergoing elective cesarean section under spinal anesthesia.

Spinal anesthesia administered for elective cesarean section as part of routine clinical care.

Expérimental: Arm 2 - Propofol TCI

Thirty women undergoing elective cesarean section under general anesthesia using target-controlled infusion of propofol.

General anesthesia using target-controlled infusion of propofol for elective cesarean section.

Comparateur actif: Arm 3 - Thiopental-Sevoflurane

Thirty women undergoing elective cesarean section under general anesthesia with thiopental induction and sevoflurane maintenance.

Thiopental was administered intravenously for induction of general anesthesia in women undergoing elective cesarean section. Anesthesia was subsequently maintained with sevoflurane.

Sevoflurane was administered by inhalation for maintenance of general anesthesia during elective cesarean section, following intravenous induction with thiopental.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Maternal Plasma TBARS Concentration
Délai: Before anesthesia, during cesarean delivery, and 2 hours postoperatively.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in maternal plasma. Concentrations were compared across the three anesthesia groups and assessed at three perioperative time points. Values are expressed in mmol/L.

Before anesthesia, during cesarean delivery, and 2 hours postoperatively.
Umbilical Cord Venous Plasma TBARS Concentration
Délai: At delivery (umbilical cord venous blood sampling).

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in mmol/L.

At delivery (umbilical cord venous blood sampling).
Placental Tissue TBARS Concentration
Délai: At delivery, immediately following placental removal.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in µmol/g of tissue.

At delivery, immediately following placental removal.
Maternal Plasma Hydrogen Peroxide (H2O2) Concentration
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Hydrogen Peroxide (H2O2) Concentration
Délai: At delivery (umbilical cord venous blood sampling).

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Superoxide Anion (O2-) Concentration
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Superoxide Anion (O2-) Concentration
Délai: At delivery (umbilical cord venous blood sampling).

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Nitrite (NO2-) Concentration
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Nitrite (NO2-) Concentration
Délai: At delivery (umbilical cord venous blood sampling).

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Erythrocyte Superoxide Dismutase (SOD) Activity
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Superoxide Dismutase (SOD) Activity
Délai: At delivery (umbilical cord venous blood sampling).

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Superoxide Dismutase (SOD) Activity
Délai: At delivery, following placental removal.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Reduced Glutathione (GSH) Concentration
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in maternal erythrocyte lysates. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL RBC.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Reduced Glutathione (GSH) Concentration
Délai: At delivery (umbilical cord venous blood sampling).

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in erythrocyte lysates from umbilical cord venous blood. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL RBC.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Reduced Glutathione (GSH) Concentration
Délai: At delivery, following placental removal.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Catalase (CAT) Activity
Délai: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Catalase (CAT) Activity
Délai: At delivery (umbilical cord venous blood sampling).

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Catalase (CAT) Activity
Délai: At delivery, following placental removal.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Umbilical Cord Blood pH
Délai: At delivery (umbilical cord blood sampling).

Umbilical cord blood pH measured by blood gas analysis immediately after delivery to assess neonatal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Oxygen (pO₂)
Délai: At delivery (umbilical cord blood sampling).

Partial pressure of oxygen (pO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal oxygenation at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Carbon Dioxide (pCO₂)
Délai: At delivery (umbilical cord blood sampling).

Partial pressure of carbon dioxide (pCO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Base Excess (BE)
Délai: At delivery (umbilical cord blood sampling).

Base excess (BE) measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Lactate Concentration
Délai: At delivery (umbilical cord blood sampling).

Lactate concentration measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Maternal Venous Blood pH
Délai: Intraoperatively, during cesarean delivery.

Maternal venous blood pH measured by blood gas analysis during cesarean delivery to assess maternal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Oxygen (pO₂)
Délai: Intraoperatively, during cesarean delivery.

Partial pressure of oxygen (pO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal venous oxygenation. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Carbon Dioxide (pCO₂)
Délai: Intraoperatively, during cesarean delivery.

Partial pressure of carbon dioxide (pCO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal acid-base and respiratory status. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Intraoperatively, during cesarean delivery.
Délai: Intraoperatively, during cesarean delivery.

Lactate concentration measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Base Excess (BE)
Délai: Intraoperatively, during cesarean delivery.

Base excess (BE) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic acid-base status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal White Blood Cell Count (WBC)
Délai: Intraoperatively and 2 hours after delivery.

Maternal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess maternal hematological status. Values were compared across the three anesthesia groups. Results are expressed in ×10⁹/L.

Intraoperatively and 2 hours after delivery.
Maternal C-Reactive Protein (CRP) Concentration
Délai: Intraoperatively and 2 hours after delivery.

Maternal C-reactive protein (CRP) concentration measured in venous blood to assess maternal inflammatory status. Values were compared across the three anesthesia groups. Results are expressed in mg/L.

Intraoperatively and 2 hours after delivery.
Intraoperatively and 2 hours after delivery.
Délai: 48-72 hours after birth.

Neonatal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess neonatal hematological status. Values were compared across the three maternal anesthesia groups. Results are expressed in ×10⁹/L.

48-72 hours after birth.
Neonatal C-Reactive Protein (CRP) Concentration
Délai: 48-72 hours after birth.

Neonatal C-reactive protein (CRP) concentration measured in venous blood to assess neonatal inflammatory status. Values were compared across the three maternal anesthesia groups. Results are expressed in mg/L.

48-72 hours after birth.
Maternal Mean Arterial Pressure (MAP)
Délai: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.

Maternal mean arterial pressure (MAP) was calculated from noninvasively measured systolic and diastolic arterial blood pressure values. Measurements were obtained before anesthesia and at 2-minute intervals after anesthesia initiation. MAP values were compared across the three anesthesia groups and expressed in mmHg.

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.
Maternal Heart Rate (HR)
Délai: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.

Maternal heart rate (HR) measured by standard intraoperative monitoring before anesthesia and at 2-minute intervals after anesthesia initiation. Measurements were compared across the three anesthesia groups. Results are expressed in beats per minute (bpm).

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.
Patient-Reported Anesthesia-Related Adverse Effects
Délai: On the first postoperative day (24 hours after anesthesia).

Anesthesia-related adverse effects were assessed using the Bauer questionnaire on the first postoperative day. Ten symptoms were evaluated: postoperative pain, drowsiness, thirst, hoarseness, sore throat, nausea and vomiting, feeling cold, difficulty concentrating, pain at the anesthetic administration site, and shivering. The outcome was expressed as the number and percentage of patients reporting each adverse effect, separately for each anesthesia group.

On the first postoperative day (24 hours after anesthesia).
Intraoperative Awareness During General Anesthesia
Délai: On the first postoperative day (24 hours after anesthesia).

Intraoperative awareness was assessed in patients receiving general anesthesia using the modified Brice questionnaire. Patients were asked about their last memory before anesthesia, first memory after awakening, any recollection of events during surgery, and dreams during anesthesia. The occurrence of reported intraoperative awareness was compared between the propofol TCI and thiopental-sevoflurane groups. The outcome was expressed as the number and percentage of patients reporting intraoperative awareness.

On the first postoperative day (24 hours after anesthesia).
Neonatal Apgar Score at 1 Minute
Délai: 1 minute after birth.

Neonatal condition was assessed using the Apgar score at 1 minute after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

1 minute after birth.
Neonatal Apgar Score at 5 Minutes
Délai: 5 minutes after birth.

Neonatal condition was assessed using the Apgar score at 5 minutes after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

5 minutes after birth.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 novembre 2022

Achèvement primaire (Réel)

19 février 2024

Achèvement de l'étude (Réel)

19 février 2024

Dates d'inscription aux études

Première soumission

31 octobre 2026

Première soumission répondant aux critères de contrôle qualité

5 novembre 2026

Première publication (Réel)

12 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared because data sharing was not included in the original study protocol or informed consent procedures.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner